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ABSTRACT
Objectives: EULAR and ACR are jointly supporting multi-phase development
of SLE classification criteria based on weighted criteria and a continuous 
probability scale. Prior steps included item generation, item reduction, and 
hierarchical organization of candidate criteria using an evidence-based 
approach. Our objectives were to determine relative weights using 
multicriteria decision analysis (MCDA) and to set a preliminary threshold 
score for SLE classification.
Methods: An SLE Expert Panel (8 European, 9 North American) submitted 
164 real, unique cases with a wide range of SLE probability in a standardized
format. Using the candidate criteria, experts scored and rank-ordered 20 
representative cases. At an in-person meeting, experts reviewed inter-rater 
reliability of scoring, further refined criteria definitions, and participated in an
MCDA exercise. Based on expert consensus decisions on pairwise 
comparisons of criteria, 1000mindsTM software calculated criteria weights and
rank-ordered the remaining 164 cases based on their additive scores. The 
score of the lowest-ranked case for which complete expert consensus was 
achieved defined the threshold classification score.
Results: Inter-rater reliability of scoring cases with the candidate criteria 
was good. MCDA involved 74 pairwise decisions and was repeated for the 
arthritis and mucocutaneous domains when the initial ranking of some cases 
did not match expert opinion. After criteria weights and additive scores were 
re-calculated once, experts reached consensus for SLE classification for all 
cases scoring >83. 
Conclusions: Using an iterative process, the candidate criteria definitions 
were refined, preliminary weights were calculated, and a preliminary 
threshold score for SLE classification was determined. 
INTRODUCTION
A multinational effort to develop new classification criteria for systemic lupus
erythematosus (SLE) for clinical research, jointly supported by the European 
League Against Rheumatism (EULAR) and American College of 
Rheumatology (ACR), is underway. The overarching goal is to develop a 
system that identifies potential participants for clinical research studies, 
requiring a degree of homogeneity among subjects while simultaneously 
dealing with the extreme heterogeneity of SLE.[1] The aim was to design a 
system with the maximum combination of sensitivity and specificity for SLE, 
retaining face validity. While the classification criteria are not intended for 
diagnosis or clinical care, it is acknowledged that the only available “gold 
standard” for the presence of SLE is expert clinician opinion.  
A 12 member Steering Committee was formed with input from EULAR and 
ACR leadership to oversee a four-phase process.[2] In Phase 1, items were 
collected through a Delphi exercise,[3] early SLE cohort,[4] and SLE patient 
survey.[5] During Phase 2, the list of potential criteria was narrowed using 
nominal group technique.[6, 7] Phase 3 began with a literature review for 
test performance characteristics of candidate criteria, and data-driven 
organization of criteria into domains.[1] This report outlines the latter part of 
Phase 3: criteria weighting and threshold score identification through a 
consensus-based multicriteria decision analysis (MCDA) approach.[8-10] The 
goal was to develop a criteria system producing a continuous measure of the
relative probability that a case (i.e. particular combination of clinical 
features) could be characterized as SLE, and a threshold score above which a
case could be definitely classified as SLE for clinical research.
METHODS
An international panel of SLE experts collected and rank-ordered patient 
case scenarios, participated in a 1.5-day in-person consensus meeting, and 
held post-meeting discussions by email and telephone. 
SLE Expert Panel. The Steering Committee invited six additional experts 
(three European, three North American) to form a 17 person SLE Expert 
Panel (“SLE experts”) to assist with this phase and establish external validity 
of the criteria development process.
Development of patient case scenarios. Each of the 17 SLE experts 
submitted 10 de-identified real cases based on patients from his/her own 
cohort in a standardized online form using REDCap (Research Electronic Data
Capture), a secure, web-based application for research studies.[11] Each 
expert was asked to submit five cases with “definite” or “likely” SLE based 
on clinical judgment, and five cases in which they had considered but 
ultimately did not diagnose SLE and/or diagnosed a condition mimicking SLE 
such as rheumatoid arthritis, other inflammatory arthritis, Sjögren’s 
syndrome, antiphospholipid antibody syndrome, or viral infection. 
Rank ordering and scoring of case scenarios. From 164 de-identified 
cases, three authors of this manuscript (KHC, RPN, SKT) chose a 
representative sample of 20 reflecting a range of possible SLE cases. Each 
case was abstracted into standardized paragraph format and SLE experts 
were asked to rank the cases based on their confidence that the case should 
be classified as SLE. This exercise introduced SLE experts to the challenge of
assessing the relative influence of individual criteria in pointing towards or 
away from SLE. 
SLE experts then scored each of the 20 cases using a standardized online 
REDCap form containing data fields reflecting the draft SLE classification 
criteria as of September 2016, based on the Phase 2 nominal group 
technique exercise[7] and subsequent work by the Steering Committee.[1] 
The REDCap form included 10 domains; each domain included 2-6 options 
(e.g. mucocutaneous domain: “none”, “non-scarring alopecia”, “oral ulcers”, 
“subacute cutaneous lupus”, “acute cutaneous lupus”, “discoid lupus”). 
Experts were provided written instructions for scoring and a list of proposed 
definitions for each criterion. The instructions specified that within each 
domain, criteria were ordered from least to most supportive of SLE, and if 
multiple criteria were present in one domain only the single criterion furthest
down the list (i.e. most supportive of SLE) should be scored. The instructions 
specified that a criterion should not be scored if a cause more likely than SLE
existed (e.g. other autoimmune disease, malignancy, medication).
In-person consensus meeting, November 2016. During the 1.5 day in-
person meeting, RPN and AH moderated discussions among SLE experts 
leading to consensus decisions. Goals of this meeting included achieving full 
consensus on criteria definitions, calculation of criteria weights via a 
multicriteria decision analysis (MCDA) exercise, and establishment of a 
threshold score for SLE classification.
a) Review of case scoring and refinement of criteria. Experts 
reviewed a summary of the REDCap scoring exercise. Discrepancies
in scoring individual cases were discussed in depth to understand 
the underlying reasons. Criteria definitions were discussed in the 
context of these discrepancies and refined based consensus 
agreement. 
b) MCDA to determine weights. The MCDA exercise is based on the 
PAPRIKA method,[12] an acronym for Potentially All Pairwise 
RanKings of all possible Alternatives, as implemented by 
1000mindsTM software (www.1000minds.com). This method and 
software have been used extensively since 2010 for developing 
disease classification criteria.[8, 9, 13] Experts voted on a series of 
pairwise decisions about hypothetical cases, each defined by two 
criteria from two domains. For example: hypothetical case A: “oral 
ulcers” (mucocutaneous domain) and “acute pericarditis” (serositis 
domain) vs. hypothetical case B “alopecia” (mucocutaneous 
domain) and “pleural effusion” (serositis domain). SLE experts were 
asked to decide whether they would more likely classify 
hypothetical case A or B as SLE, presuming all else was equal about 
the cases. Voting was conducted anonymously, but where opinions 
diverged cases were discussed until full consensus was reached. 
Such pairwise-ranking questions were repeated with different pairs 
of hypothetical cases – always involving trade-offs between different
combinations of criteria, two at a time – until enough information 
about expert preferences had been collected to determine relative 
criteria weights for all criteria. Each time experts ranked a pair, all 
other cases that could be pairwise ranked via the logical property of
‘transitivity’ were identified and eliminated. For example, if experts 
ranked hypothetical case A over B and B over C, then, by 
transitivity, A is also ranked over C (and the method would not ask 
members to choose between A and C). This procedure ensures the 
number of pairwise-ranking questions posed is kept to a minimum, 
and experts end up having pairwise ranked all possible cases 
defined on two criteria at a time, explicitly or by transitivity. 
Consensus decisions were entered into 1000mindsTM software, 
which uses linear programming techniques to derive weights for 
each criterion.[12]
c) Assessment of the face validity of the weights. Criteria 
weights were summed to produce an additive score for each case. 
Only the highest-weighted criterion in each domain was counted 
toward the additive score, as specified in the written instructions 
(Table 1). The remainder of the 164 cases were scored and 
arranged in rank order from highest to lowest score. SLE experts 
reviewed a spreadsheet listing the criteria present in each of the 
164 cases and anonymously voted whether they would classify each
as SLE. For cases where expert opinion differed, RPN facilitated 
discussion to achieve full consensus about case classification. Cases
were discussed in descending rank order (confidence that the case 
should be classified as SLE) until agreement on classifying as SLE 
could not be reached.
d) Determination of an upper threshold score. The score of the 
last case for which the group achieved consensus on classification 
as SLE was assigned as the initial threshold score.
e) Review of cases below the threshold. The cases with scores 
immediately below the initial threshold were individually reviewed. 
SLE experts reached consensus that several of these should have 
been classified as SLE. The experts reviewed the criteria present in 
those cases and discussed whether the initial criteria weights were 
consistent with expert opinion about their relative importance in 
SLE.
f) Weighting and upper threshold revision. The MCDA exercise 
was repeated once for those criteria whose calculated weights were 
inconsistent with expert opinion. Weights for all criteria were re-
calculated using 1000mindsTM and additive scores were re-
calculated. SLE experts again anonymously voted on classifying 
each case as SLE, followed by a discussion facilitated by RPN to 
achieve consensus. The score of the last case for which expert 
consensus was achieved was the provisional full consensus upper 
threshold score. 
Determining a lower threshold score. SLE experts attempted to set not 
only an upper threshold for definite SLE classification, but also a lower 
threshold for very low probability for classification. SLE experts discussed 
that individuals with scores falling between these two thresholds might be 
candidates for inclusion in observational studies or SLE prevention trials. 
These patients could be considered as “potential” SLE (also labeled probable,
possible or incomplete lupus, or undifferentiated connective tissue disease in
the past). Due to insufficient time to perform this exercise at the November 
2016 meeting, the lower threshold was addressed in a series of emails, 
secondary exercises, and conference calls in the next two months. SLE 
experts were asked to rate the cases that fell below the upper threshold 
score as “probable SLE”, “possible SLE”, or “unlikely SLE”. The score of the 
case for which ≥70% indicated “unlikely SLE” was assigned as the lower 
threshold. 
RESULTS
At the in-person meeting, SLE experts agreed that classification as SLE 
means a patient is appropriate for inclusion in SLE clinical research—and that
classification as SLE should not guide clinical decisions about SLE diagnosis 
or treatment. Experts agreed that the threshold score should have high 
specificity for SLE, ensuring a high degree of homogeneity among classified 
patients and facilitating comparisons across clinical studies. SLE experts 
reached consensus that patients with overlap syndromes could be classified 
as SLE if they met SLE classification criteria, allowing clinical investigators to 
decide whether to include or exclude patients with overlap syndromes in 
specific research studies. 
Review of scoring and criteria refinement. There was considerable 
inconsistency between SLE experts using the online REDCap form to score 
cases. Each expert had scored a total of 200 items (10 domains in each of 20
cases); all 17 experts scored 127/200 (64%) domains exactly the same. 
Reasons for discrepant data entry were explored in detail through group 
discussion. These included human error in data entry, not following the 
instructions, variability in interpreting the candidate criteria based on 
context, and different interpretations of criteria definitions (see Supplement
1 for details).
Review of the rank-ordering exercise. There was agreement on the 
cases that the majority of SLE experts ranked the highest and lowest, but a 
spectrum of ranking for cases in between (Figure 1). This reflected the 
different relative weights that individual experts attached to particular 
criteria.  
MCDA to determine consensus weights using 1000mindsTM software. 
SLE experts anonymously voted on 74 pairs of hypothetical cases. When 
consensus was lacking, members discussed rationale for choosing 
hypothetical case A vs. case B until consensus was reached. Sometimes it 
was agreed that hypothetical cases A and B were equally likely to be SLE. For
a handful of pairwise comparisons, consensus could not be reached and the 
decision was to skip that comparison and approach their relativity from other
pairwise comparisons. Significant changes to the classification criteria during
this stage included:
 Mucocutaneous and musculoskeletal domains. SLE experts decided 
that observation by a clinician should be required for consistency with 
other clinical domains. The definition of clinician-observed was broadened
to include physical examination or review of a photograph. 
 Neurologic domain. Due to disagreement over whether seizure or 
cranial neuropathy was more specific for SLE (the SLICC[15] and ACR 
1982[16] manuscripts did not present the specificity of these individual 
items), and because the prevalence of cranial neuropathy is very low in 
SLE (and none of the 167 patient cases had cranial neuropathy), the 
group reached consensus to remove cranial neuropathy. 
 Renal domain. SLE experts decided that Class VI lupus nephritis was not 
specific for SLE based on clinical experience and lack of published data, 
and agreed upon removing Class VI nephritis. Importantly, since historical 
manifestations are included in the scoring system, previous evidence of 
class II, III, IV, or V lupus nephritis would be fully accounted for. These 
steps resulted in the updated definitions depicted in Table 1.

Table 1. Provisional SLE classification criteria organization and 
definitions
Opening Statements:
• A history of a positive ANA by Hep 2 immunofluorescence ≥1:80 is required for 
consideration of a person for SLE classification. 
• For each criterion, do not score if a cause more likely than SLE exists (such as 
infection, malignancy, medication, rosacea, endocrine disorder, other autoimmune 
disease). 
• Occurrence of a criterion on at least one occasion is sufficient. 
• Criteria need not occur simultaneously.
• At least one clinical criterion must be present.
• Within each domain, only the highest weighted criterion is counted toward the 
total score. 
Clinical domains and criteria
Constitutional 
 Fever: >38.3 Celsius with no other source identified
Hematologic 
 Leukopenia: WBC <4,000/mm3
 Thrombocytopenia:  Platelets <100,000/mm3
 Autoimmune hemolysis:  (1) evidence of hemolysis, such as reticulocytosis, 
low haptoglobin, elevated indirect bilirubin, elevated LDH and (2) positive 
Coomb’s (direct antiglobulin) test
Neuropsychiatric 
 Delirium:  characterized by (1) change in consciousness or level of arousal with
reduced ability to focus, and (2) symptom development over hours to <2 days, 
and (3) symptom fluctuation throughout the day, and (4) either (4a) 
acute/subacute change in cognition (e.g. memory deficit or disorientation), or 
(4b) change in behavior, mood, or affect (e.g. restlessness, reversal of 
sleep/wake cycle, etc.)
 Psychosis:  characterized by (1) delusions and/or hallucinations without insight
and (2) absence of delirium
 Seizure:  primary generalized seizure or partial/focal seizure, with independent 
description by a reliable witness. If EEG is performed, abnormalities must be 
present
Mucocutaneous 
 Non-scarring alopecia, observed by a clinician*
 Oral ulcers, observed by a clinician*
 Subacute cutaneous lupus (SCLE) or discoid lupus (DLE):  SCLE is 
characterized by annular or papulosquamous (psoriasiform) cutaneous eruption 
observed by a clinician,* usually photodistributed. If skin biopsy is performed, 
typical changes must be present.[17] DLE is characterized by erythematous-
violaceous cutaneous lesions with secondary changes of atrophic scarring, 
dyspigmentation, often follicular hyperkeratosis/plugging (scalp), observed by a 
clinician,* leading to scarring alopecia on the scalp. Lesions have a preference 
for the head and neck, especially the conchal bowl, but may be found in nearly 
any location. If skin biopsy is performed, typical changes must be present.[17]
 Acute cutaneous lupus:  Malar rash (localized) or maculopapular rash 
(generalized) observed by a clinician,* with or without photosensitivity. If skin 
biopsy is performed, typical changes must be present.[17]
Serositis 
 Pleural or pericardial effusion:  imaging evidence (such as ultrasound, x-ray,
CT scan, MRI) of pleural or pericardial effusion, or both
 Acute pericarditis: ≥2 of: (1) pericardial chest pain (typically sharp, worse 
with inspiration, improved by leaning forward), (2) pericardial rub, (3) EKG with 
new widespread ST-elevation or PR depression, (4) new or worsened pericardial 
effusion on imaging (such as ultrasound, x-ray, CT scan, MRI)
Musculoskeletal 
 Synovitis in ≥2 joints:  characterized by joint swelling and tenderness, 
observed by a clinician*
Renal 
 Proteinuria >0.5g/24h: on 24 hour urine collection or spot urine protein-to-
Face validity of the weights and initial upper threshold score. The 
additive score ranged 0-201 for the 164 cases. SLE experts reviewed the 
cases in rank order from highest to lowest score and reached consensus on 
classifying the 69 highest-scored cases as SLE. The group was unable to 
reach full consensus for a case with a score of 70; this patient had oral 
ulcers, leukopenia, low C3 or C4, and positive anti-dsDNA. The last case for 
which experts reached consensus (17/17 votes) for classification as SLE had 
a score of 71, and an initial upper threshold score was set as >70.
Revising criteria weights and provisional upper threshold score. The 
experts reviewed cases scored 60-70. Many of these cases had arthritis and 
most experts had voted to classify them as SLE. Therefore, the group felt 
that the weight assigned to arthritis was too low. After reviewing the specific 
criteria present in these cases, the mucocutaneous domain was re-organized
based on expert consensus: acute cutaneous lupus was assigned the most 
influential position because it is most specific, and subacute cutaneous lupus
and discoid lupus were grouped together and less influential than acute 
cutaneous lupus. Anonymous voting was repeated for pairwise comparisons 
including arthritis and mucocutaneous criteria. 1000mindsTM software re-
calculated relative weights for all criteria and re-scored all cases using the 
revised weights.
After this second round of MCDA, arthritis received a greater weight than 
prior, now identical to the weight of pleural or pericardial effusion. Acute 
cutaneous lupus was assigned the same weight as acute pericarditis and 
anti-dsDNA (Table 2). The group repeated the anonymous voting exercise 
and reached consensus about the 82 highest-scored cases. Experts were 
unable to reach full consensus for the same case that determined the initial 
threshold. As that case now had a score of 83 using the revised criteria 
weights, a provisional consensus threshold was set as >83. Provisional 
criteria weights resulting from the MCDA exercise are shown in Table 2.
Table 2. Provisional SLE classification criteria weights determined 
by a multicriteria decision analysis exercise
Clinical domains and 
criteria
Weig
ht 
(point
s)
Immunologic domains and 
criteria
Weig
ht 
(point
s)
Constitutional Antiphospholipid antibodies 
 Fever 13
 Anticardiolipin IgG >40 
GPL units or anti-β2GP1 
IgG >40 units or lupus 
anticoagulant positive
13
Hematologic Complement proteins 
 Leukopenia 12  Low C3 or low C4 19
 Thrombocytopenia 26  Low C3 and low C4 27
 Autoimmune hemolysis 28 SLE-specific antibodies 
Neuropsychiatric  Anti-dsDNA antibody 38
 Delirium 12  Anti-Smith antibody 40
 Psychosis 20
 Seizure 34
Mucocutaneous 
 Non-scarring alopecia 13
 Oral ulcers 14
 Subacute cutaneous or 
discoid lupus* 29*
 Acute cutaneous lupus 38
Serositis 
 Pleural or pericardial 
effusion 34
 Acute pericarditis 38
Musculoskeletal 
 Synovitis in ≥2 joints 34
Renal 
 Proteinuria >0.5g/24h 27
 Renal biopsy with Class 
II or V lupus nephritis 55
 Renal biopsy with Class 
III or IV lupus nephritis 74
*Subacute cutaneous lupus and discoid lupus each received a weight of 29, thus 
they were combined as one criterion
Lower threshold score. SLE experts individually rated the 82 cases below 
the upper threshold score as “probable SLE”, “possible SLE”, or “unlikely 
SLE” after the ACR 2016 meeting. The distribution of expert opinion is shown
in Figure 2. The score of the case for which ≥70% indicated “unlikely SLE” 
was 27. Only seven of 52 unique cases (13.5%) included in this exercise 
would be classified as “unlikely SLE” based on this lower threshold, and the 
remaining 86.5% would potentially be candidates for inclusion into 
observational or preventive studies. Through a series of telephone calls and 
emails, it became clear expert opinion varied considerably concerning the 
cases below the upper threshold. Additionally, the terms “probable”, 
“possible” and “unlikely” were not being uniformly interpreted in this 
exercise and the duration of manifestations had not been specified. The SLE 
experts decided against assigning a lower threshold because it would 
exclude only a few cases from clinical studies. 
DISCUSSION
In Phase 3 of this SLE classification criteria development project, we applied 
a consensus-based, data-driven MCDA approach to assign criteria weights 
and identify a threshold score for SLE classification for clinical research. This 
exercise resulted in provisional criteria weights that have face validity and 
are additive, providing a continuous measure of increasing likelihood for SLE 
based on combinations of criteria. While full consensus of the 17 SLE experts
was reached for cases scoring >83 points, it became evident that expert 
opinions varied for cases with mid-range or low scores. Many cases with 
scores just under 83 were still considered SLE by the majority of experts, but 
in an additional exercise focusing cases below the threshold for definite SLE, 
very few were deemed “unlikely SLE” by ≥70% of experts.
This stage was largely based on the items resulting from the Phase 2 
nominal group technique exercise[7] and on evidence from our literature 
review of the sensitivity and specificity of the individual candidate criteria.[1]
These efforts followed rigorous data-driven and expert-guided criteria 
development methodology in order to ensure high face and content validity 
of the items, and high discriminant validity of the criteria set.[19, 20] 
However, our literature review also revealed knowledge gaps about the 
sensitivity and specificity of some of the newly proposed criteria, thus expert
consensus opinion was critical for decision making. 
Consistent with developing other sets of classification criteria,[21, 22] there 
were significant discrepancies in ranking 20 cases regarding likelihood of SLE
classification. Discussions centered on two aspects: 1) the quality and thus 
specificity of clinical and serological manifestations, and 2) attribution of 
manifestations to SLE versus other connective tissue diseases. Some experts
expressed concern about misinterpretation of rosacea as acute cutaneous 
lupus, and about false positive anti-dsDNA via ELISA, each of which would 
reduce the specificity of the proposed classification system. To address these
concerns, SLE experts agreed to include detailed definitions for each 
criterion to mitigate the risk of misinterpreting clinical signs and symptoms. 
Because particular laboratory assays (e.g. Farr method for anti-dsDNA) are 
not uniformly available in all clinical settings, SLE experts decided that the 
testing method would not be specified, enabling SLE classification in a wide 
range of clinics.
The attribution of manifestations to SLE was discussed at length. For some of
the cases, SLE experts were uncertain about how to interpret particular 
findings when SLE and another disease, such as primary antiphospholipid 
syndrome or Sjögren’s syndrome, seemed equally likely. It became apparent 
that not all these decisions could be made with certainty, and that SLE 
experts from different centers could reach opposing conclusions. 
The decision to exclude Class VI lupus nephritis was unanimous, given the 
lack of specificity of this end-stage finding. The discussions leading to the 
consensus elimination of mononeuropathy and cranial neuropathy were of 
greater interest. It was first mentioned that the specificities of these entities 
differed and that mononeuropathy is not specific for SLE. The group reached 
full consensus to eliminate mononeuropathy, and cranial neuropathy was 
initially retained. The group then discussed that cranial neuropathy is a very 
rare presenting sign in SLE[23] and that none of the 164 cases had cranial 
neuropathy. Experts reached a unanimous decision that the low prevalence 
of cranial neuropathy in SLE warranted eliminating it as a criterion. 
Using a data-driven approach based on literature review[1] combined with 
an expert-driven MCDA process based on real patient cases, this third phase 
of the SLE classification project has led to precisely-defined criteria with 
individual weights derived through consensus decisions by 17 international 
SLE experts. The individual criteria weights have face validity, and taken 
together they depict current expert understanding of SLE. The preliminary 
classification criteria resulting from this third phase are being refined and 
validated in a large, distinct set of patient cases to finalize the project.
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